The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia

Department of Psychiatry, Chonnam National University Medical School, Gwangju 501-746, Republic of Korea.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (Impact Factor: 3.69). 04/2012; 38(2):228-35. DOI: 10.1016/j.pnpbp.2012.04.004
Source: PubMed


This study aimed to evaluate the subjective well-being and attitudes toward antipsychotic medication of patients with schizophrenia who had switched to paliperidone extended release (ER).
A total of 291 patients with schizophrenia treated with antipsychotics participated in this open-label, 24-week switching study. The primary outcome measures were the Subjective Well-Being under Neuroleptic Treatment Scale-short version (SWN-K) and the Drug Attitude Inventory (DAI). The Krawiecka scale, Clinical Global Impression-Schizophrenia (CGI-SCH), Personal and Social Performance scale (PSP) were used to evaluate psychopathology and psychosocial functioning, respectively.
Data from a total of 243 subjects who received the study medication and had at least one follow-up assessment without a major protocol violation were analyzed. Scores on the DAI and SWN-K showed significant improvement between baseline and end-point measurements beginning during the second week. Scores on the Krawiecka scale, all five subscales of the CGI-SCH scale, and the PSP scale were also significantly improved at the end point compared with the baseline. Significant predictors of improvements in the SWN-K and DAI after a switch to paliperidone ER were baseline scores, reductions in scores on the Krawiecka scale, and previous risperidone use. A clinically relevant increase in body weight (≥7% weight gain) occurred in one-fourth of the participants who completed the 24-week study.
Switching to paliperidone ER improved the subjective well-being and attitudes towards antipsychotic medication in patients with schizophrenia. Exploratory analyses revealed that these improvements were particularly pronounced in patients who had been treated with risperidone before treatment with paliperidone ER.

12 Reads
  • Source
    • "The present study analyzed the pooled data from two openlabel investigations of patients with schizophrenia, which were conducted by the Johnson and Johnson family of companies (Choi et al., 2013; Kim et al., 2012; Na et al., 2013). The protocols for these studies, the Paliperidone Effectiveness Study to Evaluate the Subjective Symptom Change (PASS) and the Paliperidone Extended Release (ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (PERFECT), were filed with the United States Food and Drug Administration prior to their initiation ( "

  • Source
    • "The present study analyzed the pooled data from two openlabel investigations of patients with schizophrenia, which were conducted by the Johnson and Johnson family of companies (Choi et al., 2013; Kim et al., 2012; Na et al., 2013). The protocols for these studies, the "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: We aimed to examine the longitudinal relationship between the personal and social functioning and anxiety symptoms in patients with schizophrenia. For this purpose, we confirmed the validity of the anxiety subscale of the Symptom-Checklist-90-Revised (SCL-90-R) and then applied the latent growth modeling method for longitudinal causal relationships. Methods: Five hundred and seventy-eight patients diagnosed with schizophrenia were evaluated and 369 patients were included in the study at baseline. After conducting Rasch model analyses for the validation of the anxiety subscale in the SCL-90-R, we applied latent growth model to determine the causal relationship between the PSP and the anxiety symptoms. Results: The validity of the anxiety subscale of the SCL-90-R was confirmed based on the Rasch rating model, where the criteria for Infit, Outfit, item difficulty, and point-measure correlations were satisfied. The results from the latent growth model showed that the intercept and slope (rate of change) of the PSP negatively predicted the slope of anxiety symptoms along the longitudinal trajectory. Together with previous studies examining the predictive role of anxiety symptoms on quality of life, our longitudinal findings lend evidence for bidirectional effects between quality of life and anxiety symptoms. The transactional nature of the relationship between anxiety symptoms and quality of life warrant further investigation using a longitudinal cross-lagged design. Conclusion: The anxiety subscale of the SCL-90-R may be utilized by clinicians and researcher to make inferences about quality of life in addition to assessing anxiety symptoms in patients with schizophrenia.
    Journal of Affective Disorders 10/2015; 190:12-18. DOI:10.1016/j.jad.2015.09.048 · 3.38 Impact Factor
  • Source
    • "Various variables will be investigated to evaluate responses such as Krawiecka scale, CGI-SCH-S, I, PSP, vital Signs, DIEPSS, clinical Lab, height, weight, waist circumference. There were published articles about these study.21,22 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Paliperidone extended-release tablet (paliperidone ER) is a new oral psychotropic agent developed for schizophrenia treatment. There have been some studies about paliperidone's good efficacy and tolerability. Clinicians appear to change the antipsychotic medication to paliperidone ER. However, it is not known what patients are favorable responsive to paliperidone ER. The aim of this study was to evaluate the characteristics of early responders and investigate predictors of acute response when the medications changed to paliperidone ER. Data were analyzed from schizophrenic patients who participated in a multi-center, open-label, non-comparative clinical trial. Total 320 patients were examined in this study. Sociodemographic, psychopathology, social function and metabolic data were evaluated. Unpaired t-test for continuous and χ(2) for categorical data, respectively, were used to compare early responder and non-responders. Logistic regression analysis was used to establish a prediction model. 38.7% of study subjects (124 of 320) responded to paliperidone ER treatment. Logistic regression analysis showed that a good paliperidone ER response was more likely when patients were social drinkers, when patients had started medication at inpatient, when negative symptoms were less severe, and when patients' social relationship and self-care were better. Early response to paliperidone ER treatment is associated with less negative symptoms and good social relationships and self-care. Strategies to reduce these symptoms may contribute to early response to paliperidone ER.
    Psychiatry investigation 12/2013; 10(4):407-16. DOI:10.4306/pi.2013.10.4.407 · 1.28 Impact Factor
Show more